Skip to main content Skip to main navigation menu Skip to site footer

A rare case of fungemia by Kodamea ohmeri in a premature infant

  • Jeffry Prabowo ,
  • Luh Inta Prilandari ,
  • I Nengah Tony Rustawan ,
  • Ni Made Adi Tarini ,

Abstract

Background: Kodamaea ohmeri, is part of the Saccharomycetes that commonly used in the processing of fermented foods, but this fungus can be an emergency when it comes to patients with impaired immune systems so that fungiemia, endocarditis, peritonitis can occur. Many cases have been reported in Asia, America and Europe. This case report aims to present a rare case of fungemia caused by Kodamera ohmeri in a premature infant in neonatal intensive care unit (NICU), Prof. Dr. I.G.N.G. Ngoerah, Bali, Indonesia

Case presentation: The baby was born prematurely at 33 weeks of gestation because the mother had severe preeclampsia. The baby was admitted to the NICU with an initial diagnosis of sepsis, then blood cultures were taken and inoculated with sabouraud dextrose agar (SDA) at 37°C for 48 hours. Microscopic examination with lactophenol cotton blue staining was carried out from slide culture for 7 days in which clustered yeast cells were found.  Culture results on Saboraud Dextrose Agar (SDA) at 37˚C for 48 hours found growth of colonies that were rough, dry, and white like ivory. Identification results using VITEK-2 compact (bioMérieux®) found Kodamea ohmeri, but no antibiotic sensitivity (AST) results. The patient was treated with fluconazole empirically for 11 days, but not routinely therefore the patient got into emergency condition and died.

Conclusion: Patient’s condition eventually worsened, possibly due to the ineffective and inappropriate use of fluconazole. The condition of premature babies, most of whom are immunocompromised, can increase the severity of the disease to sepsis and eventually death.

References

  1. Li ZM, Kuang YK, Zheng YF, et al. Gut-derived fungemia due to Kodamaea ohmeri combined with invasive pulmonary aspergillosis: a case report. BMC Infect Dis. 2022;22(1):903. Published 2022 Dec 3. doi:10.1186/s12879-022-07866-6.
  2. Xie P, Wang W, Dong M. Long-term mortality predictors of ICU fungaemia. Epidemiol Infect. 2021;149:e241. doi:10.1017/S0950268821002235.
  3. Ioannou P, Papakitsou I. Kodamaea ohmeri infections in humans: A systematic review. Mycoses. 2020;63(7):636-643. doi:10.1111/myc.13094.
  4. Ferreras-Antolín L, Sharland M, Warris A. Management of Invasive Fungal Disease in Neonates and Children. Pediatr Infect Dis J. 2019;38(6S Suppl 1):S2-S6. doi:10.1097/INF.0000000000002317.
  5. Zhou M, Li Y, Kudinha T, Xu Y, Liu Z. Kodamaea ohmeri as an Emerging Human Pathogen: A Review and Update. Front Microbiol. 2021;12:736582. doi:10.3389/fmicb.2021.736582.
  6. Hasim S, Coleman JJ. Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents. Future Med Chem. 2019;11(8):869-883. doi:10.4155/fmc-2018-0465.
  7. Wang CH, Su YS, Lee WS. Necrotizing cellulitis caused by Kodamaea ohmeri fungemia in a HIV- infected patient. J Infect. 2022;84(4):579-613. doi:10.1016/j.jinf.2022.01.008.
  8. Zhou M, Yu S, Kudinha T, et al. Identification and antifungal susceptibility profiles of Kodamaea ohmeri based on a seven-year multicenter surveillance study. Infect Drug Resist. 2019;12:1657-1664. doi:10.2147/IDR.S211033.
  9. Chew KL, Achik R, Osman NH, Octavia S, Teo JWP. Genome Sequence of a Clinical Blood Isolate of Kodamaea ohmeri. Microbiol Resour Announc. 2022;11(12):e0084322. doi:10.1128/mra.00843-22.
  10. Astvad KMT, Arikan-Akdagli S, Arendrup MC. A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints. J Fungi (Basel). 2022;8(2):141. doi:10.3390/jof8020141.
  11. Frenkel M, Serhan H, Blum SE, et al. What Is Hiding in the Israeli Mediterranean Seawater and Beach Sand. J Fungi (Basel). 2022;8(9):950. doi:10.3390/jof8090950.
  12. Sathi FA, Paul SK, Ahmed S, et al. Prevalence and Antifungal Susceptibility of Clinically Relevant Candida Species, Identification of Candida auris and Kodamaea ohmeri in Bangladesh. Trop Med Infect Dis. 2022;7(9):211. doi:10.3390/tropicalmed7090211.
  13. Pathadka S, Yan VKC, Neoh CF, et al. Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries. Drugs. 2022;82(11):1193-1205. doi:10.1007/s40265-022-01751-x
  14. Ferreira EO, Mendes INVF, Monteiro SG, et al. Virulence properties and sensitivity profile of Candida parapsilosis complex species and Kodamaea ohmeri isolates from onychomycosis of HIV/AIDS patients. Microb Pathog. 2019;132:282-292. doi:10.1016/j.micpath.2019.05.012
  15. Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis. 2020;222(Suppl 3):S175-S198. doi:10.1093/infdis/jiaa394.
  16. Haidar A, Khaja F, Simms B, Elgehiny AI, Omoegbele T, Khetan N. Central line associated bloodstream infection caused by Kodamaea ohmeri in a young child. Germs. 2021;11(4):614-616. doi:10.18683/germs.2021.1298.
  17. Al-Sweih N, Khan ZU, Ahmad S, et al. Kodamaea ohmeri as an emerging pathogen: a case report and review of the literature. Med Mycol. 2011;49(7):766-770. doi:10.3109/13693786.2011.572300.
  18. Hou C. Catheter-related bloodstream infection caused by Kodamaea ohmeri in China. Infect Prev Pract. 2019;1(1):100006. doi:10.1016/j.infpip.2019.100006.
  19. García Clemente P, Romero-Gómez P, García-Rodríguez J, Cendejas-Bueno E. Optimized identification of microorganisms directly from positive blood cultures by MALDI-TOF to improve antimicrobial treatment. Rev Esp Quimioter. 2022;35(4):362-369. doi:10.37201/req/135.2021.
  20. Saha D, Sharma A, Borah N, Saikia D. The Spectrum of Pathogenic Yeast Infection in a Tertiary Care Hospital in Assam, India. Cureus. 2022;14(11):e31512. doi:10.7759/cureus.31512.
  21. El-Didamony SE, Kalaba MH, El-Fakharany EM, et al. Antifungal and antibiofilm activities of bee venom loaded on chitosan nanoparticles: a novel approach for combating fungal human pathogens. World J Microbiol Biotechnol. 2022; 38: 244. doi:10.1007/s11274-022-03425-y.
  22. Liu Y, Chen Z, Li J, et al. Extensive Diversity and Prevalent Fluconazole Resistance among Environmental Yeasts from Tropical China. Genes (Basel). 2022;13(3):444. Published 2022 Feb 28. doi:10.3390/genes13030444.
  23. Diallo K, Lefevre B, Cadelis G, et al. A case report of fungemia due to Kodamaea ohmeri. BMC Infect Dis. 2019;19(1):570. doi:10.1186/s12879-019-4208-8.
  24. Saud Al-Abbas AH, Ling JL, Muhammed J, Hussein A. Rare Kodamaea ohmeri keratitis following a trivial vegetative trauma. BMJ Case Rep. 2019;12(6):e229660. doi:10.1136/bcr-2019-229660.
  25. Vivas R, Beltran C, Munera MI, Trujillo M, Restrepo A, Garcés C. Fungemia due to Kodamaea ohmeri in a young infant and review of the literature. Med Mycol Case Rep. 2016;13:5-8. doi:10.1016/j.mmcr.2016.06.001.
  26. Jayaweera JAAS, Kothalawala M, Sooriyar S. Infected tricuspid valve myxoma with Kodamaea ohmeri: Case report. Indian J Med Microbiol. 2021;39(2):252-255. doi:10.1016/j.ijmmb.2020.12.002.
  27. Badiee P, Shokohi T, Hashemi J, et al. Comparison of in vitro activities of newer triazoles and classic antifungal agents against dermatophyte species isolated from Iranian University Hospitals: a multi-central study. Ann Clin Microbiol Antimicrob. 2023;22(1):15. doi:10.1186/s12941-023-00564-4.
  28. Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res. 2022;10:507. doi:10.12688/f1000research.28327.2.

How to Cite

Prabowo, J. ., Prilandari, L. I. ., Rustawan, I. N. T. ., & Tarini, N. M. A. (2024). A rare case of fungemia by Kodamea ohmeri in a premature infant. Intisari Sains Medis, 15(1), 340–343. https://doi.org/10.15562/ism.v15i1.1983

HTML
0

Total
0

Share

Search Panel

Jeffry Prabowo
Google Scholar
Pubmed
ISM Journal


Luh Inta Prilandari
Google Scholar
Pubmed
ISM Journal


I Nengah Tony Rustawan
Google Scholar
Pubmed
ISM Journal


Ni Made Adi Tarini
Google Scholar
Pubmed
ISM Journal